MAP2K7 and neoplasm: We treated BMD-macrophages from tumor-bearing mice for 1 h ex vivo with MEK inhibitor or vehicle; MEKi significantly increased the intensity of anti-C5aR1/CD88 on tumor macrophage cell surfaces (Fig 2G).